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Abstract
The long-term and potential rare side effects of new immunomodulating drugs for the treatment of multiple sclerosis (MS) 
are often not well known. Spontaneous case report systems of adverse drug effects are a valuable source in pharmacovigi-
lance, but have several limitations. Primary data collections within registries allow a comprehensive analysis of potential 
side effects, but face several challenges. This article will outline the chances and challenges of registry-based adverse event 
reporting, using the example of the German immunotherapeutic registry REGIMS. REGIMS is an observational, clinical 
multicenter registry that aims to assess the incidence, type, and consequences of side effects of MS immunotherapies. Patients 
treated with an approved MS medication are recruited by their physicians during routine visits in hospitals, outpatient clinics, 
and MS-specialized practices. REGIMS incorporates an electronic physician-based documentation in each center and a paper-
based patient documentation, both at baseline and regular follow-up visits. By the end of 2019, 43 REGIMS centers were 
actively recruiting patients and performing follow-up documentations. The majority of the first 1000 REGIMS patients were 
female (69.3%), had relapse-remitting MS (89.8%), and were treated with a second-line therapy. During the implementation of 
REGIMS, several logistic and procedural challenges had to be overcome, which are outlined in this paper. Pharmacovigilance 
registries such as REGIMS provide high-quality primary data from a specific patient population in a real-world care setting 
and enable pharmacovigilance research that cannot be carried out using secondary data. Despite the logistic and procedural 
challenges in establishing a multicenter pharmacovigilance registry in Germany, the advantages outweigh the drawbacks.
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Key Points 
The implementation of a multicenter pharmacovigilance 
registry such as REGIMS into routine clinical care faces 
multiple challenges that must be addressed and solved 
in the planning phase. Among them is the motivation of 
centers and participants, the IT architecture of data col-
lection, and changes in data items over time.
Registry-based data assessment allows the safety moni-
toring of highly specialized drugs for which there is 
limited experience, especially with regard to their long-
term use.
Information on patient-reported outcomes ideally 
complements the medical documentation and is gaining 
increasing relevance.
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1 Introduction
Multiple sclerosis (MS) is a complex autoimmune neurolog-
ical disease, often with an age of onset in young adulthood 
[1, 2]. Increasing disability during the course of disease 
and subsequently a reduced life expectancy are frequently 
observed in patients with MS and result in a high socioeco-
nomic burden for the population [3].
In the last 10 years, many MS treatments aiming to mod-
ify different immune functions have been newly approved 
[4, 5], representing a major change to the limited number 
of treatment options beforehand. In addition, several ongo-
ing phase II and phase III trials in the MS field will most 
likely lead to further approvals in upcoming years [6, 7]. 
However, the long-term effects and potential rare side 
effects of new treatments, especially when used in routine 
clinical care, are not well known. Thus, the treatment of 
MS patients represents an important and interesting field 
for pharmacovigilance.
Spontaneous reports of adverse drug reactions are an 
important source of post-marketing drug safety surveillance. 
However, these reports rely on the alertness and motivation 
of those who should report, while these individuals often 
have challenging daily clinical care routines. Spontaneous 
report systems, such as the German one, also do not provide 
all the information about a specific exposure to the drug and 
lack important patient characteristics, such as data on qual-
ity of life, therapy adherence, or patients’ satisfaction with 
their medication.
Here, multicenter, longitudinal registries provide a com-
prehensive design  to complement the spontaneous case 
report system within a given healthcare system. Those reg-
istries that are based on primary data collections, such as 
physician documentation of MS patients on immunomodula-
tory MS medication, allow an extensive analysis of potential 
drug side effects. They are ideally complemented by patient 
self-reports of so-called patient-reported outcomes (PROs), 
e.g., quality of life perceptions or activities of daily living. 
Medical documentation should be concise, implementable 
in the physician’s documentation during regular visits, and 
updated on a regular basis. Avoiding the need for double 
data entry is another important issue since many different 
software tools for data entry are available in outpatient ser-
vices and specialized MS practices, especially in Germany, 
and center-specific software should be used, whenever pos-
sible. However, the implementation of data items in different 
software tools for routine care imposes high logistic com-
plexity. To date, only a few pharmacovigilance registries in 
the field of MS have been implemented internationally, and 
none in Germany.
The aim of this paper is to describe the chances and chal-
lenges of registry-based adverse event (AE) reporting and, 
more generally, in pharmacovigilance, using the REGIMS 
registry, a German immunotherapeutic registry to improve 
drug safety in MS therapies, as an example.
2  Background: The Need for Registry‑Based 
Adverse Event Reporting
The introduction of new immunomodulatory substances 
during the last decade, many of them being biologicals, 
has increased the treatment options for MS significantly. 
Their use offers a number of opportunities for the treatment 
of MS, but also carries the risk of side effects. The assess-
ment of side effects (including unexpected and previously 
unknown AEs) via standardized documentation in routine 
clinical care is an established method for the data-based 
risk assessment of new substances, but has not been con-
ducted using a registry-based approach for MS patients in 
Germany before.
In order to improve the safety of these therapies in the 
treatment of MS patients and to document side effects of 
approved MS drugs, the immunotherapy registry REGIMS 
was established by the disease-oriented Competence Net-
work Multiple Sclerosis (Krankheitsbezogenes Kompetenz- 
netz Multiple Sklerose [KKNMS]), starting in November 
2013. The KKNMS was initiated in 2009 and focuses on 
various research topics that have been addressed by lead-
ing experts in the field of MS in nationwide collaborations 
[8]. The overall goal of REGIMS is to assess the incidence, 
type, and consequences of adverse drug reactions of current 
and future MS medications. Secondary aims are to identify 
patient-related factors that are associated with adverse drug 
reactions and therapy adherence, to analyze quality of life 
under therapy, and to investigate the efficacy of new sub-
stances in the course of the disease. In addition to the main 
focus on safety aspects, REGIMS includes a patient ques-
tionnaire to collect PROs on a regular basis.
2.1  Methodological Aspects
Study Design REGIMS is a national, prospective, observa-
tional (i.e., non-interventional), clinical multicenter regis-
try within the KKNMS. Participating centers are KKNMS 
network centers as well as centers that have been invited to 
participate in REGIMS if they met the criterion of providing 
regular outpatient care to MS patients. Overall, the REGIMS 
centers are made up of clinics, MS outpatient clinics, and 
MS-specialized practices. Patients with diagnosed MS or 
with a clinically isolated syndrome (CIS) and treated with an 
approved MS medication at study baseline are included. The 
study incorporates physician-based documentation in each 
center and patient-based documentation, both at baseline and 
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at regular follow-ups every 6 months. Study participants are 
recruited by their treating physicians during routine visits 
after signing informed consent.
REGIMS is constantly including new centers. By the end 
of 2019, 43 REGIMS centers were actively recruiting study 
participants and performing follow-up documentations, with 
two to four new centers joining the registry every year.
Inclusion Criteria Included in REGIMS are patients with 
a confirmed diagnosis of MS or with CIS, aged 18 years or 
older, and who are either:
• Treated de novo with a MS medication.
• Treated with natalizumab, fingolimod, mitoxantrone, 
alemtuzumab, ocrelizumab, dimethyl fumarate, teriflu-
nomide, or in the future approved immunotherapeutic 
drugs, independent of therapy duration.
• Treated with interferon-β-1a administered intramus-
cularly (IM)/subcutaneously (SC), interferon-β-1b SC, 
glatiramer acetate, or azathioprine for a maximum of 
36 months.
Exclusion Criteria Excluded from REGIMS are patients 
under 18 years, patients without a definite diagnosis of 
MS (except for CIS patients), and patients treated with 
interferon-β-1a IM/SC, interferon-β-1b SC, glatiramer ace-
tate, or azathioprine for more than 36 months.
Ethical and Data Protection Issues Patients who meet the 
inclusion criteria receive written information about the reg-
istry and sign informed consent, which has been approved 
by local ethics committees. The patient consent includes the 
collection and storage of medical data including AEs, the 
use of these data for scientific analyses, and the storage of 
personal data (e.g., name and address) that are necessary 
for the administration of the patient-based documentation 
(paper-based questionnaires).
Ethical approval was initially obtained by one ethics com-
mittee (so-called main approval), with subsequent approval 
by multiple ethics committees across all German federal 
states. Patients can withdraw their consent in the documen-
tation at any time.
Only pseudonymized data are stored in the REGIMS 
database. Personal data are not submitted to the database 
and thus are not available for the scientists carrying out 
scientific analyses. However, personal data (e.g., name and 
address) are necessary for the administration of the patient-
based documentation and are only accessible to author-
ized staff who administers the mailing of the paper-based 
questionnaires and who do not have access to the data from 
the medical documentation. These personal data are stored 
separately from the medical documentation and from the 
questionnaires.
2.2  Data Collection in REGIMS
Physician-Based Documentation (Electronic Documentation 
in the Centers) The physician-based documentation (medi-
cal documentation) is done during routine patient visits in 
the centers. The registry has five different software tools for 
data entry, enabling centers to decide which to use based 
on local needs and infrastructure and to reduce the need 
for double data entry. These web data entry tools are RED-
Cap,  Secutrial®,  MSDS®, x4T-EDC System (REGIMS plat-
form), and the web-based tool of the German MS Society 
(Deutsche Multiple Sklerose-Gesellschaft [DMSG]). For 
consenting patients, the physician-based documentation is 
done electronically in one of these software tools. From each 
tool, exports of the REGIMS data via interfaces are done on 
a regular basis, and after verification, data from the different 
software tools are merged in the study database.
Patient-Based Documentation (Paper-Based Ques-
tionnaires) In addition, a paper-based questionnaire with 
information on PROs is completed by the patients and 
sent back to the REGIMS coordination center twice in the 
first 12 months and annually thereafter. There, all ques-
tionnaires are scanned; data are checked for plausibil-
ity and subsequently imported into the database. Patient 
self-reports include quality of life, healthcare utilization, 
treatment satisfaction, and adherence, as well as different 
scales for psychosocial functions. Table 1 summarizes in 
detail items assessed at baseline and at follow-up visits 
stratified by documentation type (physician vs. patient).
Documentation of Safety Data AEs or serious adverse 
events (SAEs) can be reported to REGIMS at every rou-
tine follow-up visit in the center, irrespective of causal-
ity. In this case, documentation includes a detailed ques-
tionnaire regarding information on AEs and a rating of 
causality. AE and SAE documentation in the REGIMS 
registry is not limited to events with at least some degree 
of suspected causal association, i.e., the study nurses and 
physicians are asked to report all events, even if they rate 
the causality for an AE as “not assessable,” “unlikely,” 
or “not related.” SAEs are immediately sent to REGIMS 
via the software and reported to the marketing authoriza-
tion holder within 24 h, thus, complementing the Ger-
man spontaneous case report system. Safety reports are 
prepared according to European guidelines and sent to all 
centers every 6 months.
Quality Assurance and Data Management All partici-
pating study nurses and physicians in the REGIMS centers 
receive on-site training in data entry in order to ensure 
high data quality. Additionally, the web-based documenta-
tion performs automated data checks for completeness and 
plausibility during data entry. The processing of paper-
based patient questionnaires includes plausibility and com-
pleteness checks.
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3  Registry Participants in REGIMS until 2019
By the end of 2019, 1562 patients had been included in 
the REGIMS registry, of whom 1283 patients already had 
at least one follow-up available.
Descriptive characteristics of the first 1000 patients 
included in REGIMS are shown in Tables 2 and 3. The 
average age at baseline documentation was 38.4 years, 
with a mean age at diagnosis of 31.0 years. The majority 
of the patients were female, most had relapse-remitting 
MS (89.8%), and the median expanded disability status 
scale (EDSS) score was 2.5. Most patients were treated 
with a second-line therapy. Physician-based follow-up 
documentation was conducted with a median follow-up 
time of 5.8 months (Table 2). Natalizumab (33.1%) was 
the most frequently administered drug at baseline assess-
ment, followed by fingolimod (21.7%), alemtuzumab 
(15.9%), dimethyl fumarate (10.1%), ocrelizumab (5.3%), 
interferons (4.4%), teriflunomide (3.5%), and glatiramer 
acetate (3.4%) (Table 3).
The median number of patient-reported MS onset 
symptoms was two, with dysesthesias (53.3%), motor 
disturbances (53.0%), and impaired vision (44.4%) being 
the most frequent onset symptoms (Table 2). About two 
thirds (68.6%) of the patients had at least one comorbidity. 
Allergies (26.7%), depression (15.7%), and hypertension 
(14.6%) were the most frequently reported comorbidities 
(Table 3).
4  Discussion
Experiences gained during the implementation of the 
REGIMS registry and the results of the first 1000 included 
patients described previously can be used to address, more 
generally, the chances and challenges that have to be met if 
prospective registries are built for pharmacovigilance pur-
poses. This is discussed in more detail below.
The Relevance of Pharmacovigilance Registries The 
important role of primary data collections within pharma-
covigilance registries such as REGIMS is emerging since 
they provide high-quality data from a specific patient popu-
lation in a real-world care setting. Furthermore, they pro-
vide information about drug safety or PROs, and can address 
different research questions regarding pharmacovigilance. 
In addition, pharmacovigilance registry data are able to dis-
entangle potential causal outcomes such as a relationship 
between treatment with a highly effective drug and an AE. 
Pharmacovigilance registries with a long-standing history 
and tightly monitored data collection, such as the Swed-
ish MS registry (SMSreg), the German biologics registry 
RABBIT, or the Swedish biologics registry ARTIS, have 
highlighted the clinical relevance of primary data for moni-
toring drug safety [9–12]. Data from these registries provide 
valuable information on pharmacovigilance issues that may 
not be detected using secondary data, and add complemen-
tary information to findings from randomized controlled 
trials that underrepresent or do not include specific patient 
Table 1  Electronic and patient-based documentation in REGIMS
AE adverse event, EDSS expanded disability status scale, GAD-7 Generalized Anxiety Disorder 7 questionnaire, MS multiple sclerosis, PHQ-9 
Patient Health Questionnaire, RS-11 11-item Resilience Scale, SAE serious adverse event, SF-36 36-item Short Form Health Survey
Baseline Follow-ups
Physician documentation (electronic  
documentation in the centers)
Demographic characteristics
EDSS
MS type + prior course




Changes in MS type





Patient documentation (paper-based question-
naires at home)
Family history of MS
SF-36
satisfaction with efficacy and safety of MS  
medication





Satisfaction with efficacy and safety of MS 
medication
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subgroups [13, 14]. However, the implementation of a mul-
ticenter registry such as REGIMS into routine clinical care 
is accompanied by multiple chances and challenges. Expe-
riences with implementing and running the pharmacovigi-
lance registry REGIMS will be outlined in this section.
Ethical Approval and Judicial Contracts Due to Germa-
ny’s federal structure, difficulties regarding administrative 
modalities occurred. The study had initially been approved 
by one ethics committee (main approval). However, every 
ethical board responsible for one or more participating 
centers in each state had to accept this approval indepen-
dently because a centralized approval process only exists for 
clinical trials. Since university hospitals in Germany usu-
ally have their own ethical board, neighboring centers might 
have required two different approvals. This led to a time-
consuming procedure for ethical approval and registration 
of every new center, and was associated with considerable 
costs [15, 16].
Software Issues The medical electronic documentation 
should be feasible within the regular physician-based docu-
mentation during routine visits, avoiding the necessity for 
double data entry. This is an issue for any disease since usu-
ally different software tools for data entry are available and 
used in practice. A major strength of REGIMS is that dif-
ferent software tools can be used for the physician-based 
documentation, giving each center the possibility of using 
the locally most convenient solution. In addition, software 
tools are adaptable, e.g., newly approved drugs can rap-
idly be implemented into the tools. AEs and SAEs can be 
documented at every routine follow-up visit, irrespective of 
the visit interval length, providing further flexibility to the 
centers, as long as a minimum of one assessment is done 
per year. This ensures that potential associations between 
Table 2  Descriptive characteristics of the first 1000 REGIMS partici-
pants at baseline
CIS clinically isolated syndrome, EDSS expanded disability status 
scale, IQR interquartile range, MS multiple sclerosis, PPMS primary 
progressive multiple sclerosis, RRMS relapse-remitting multiple scle-
rosis, SD standard deviation, SPMS secondary progressive multiple 
sclerosis
a Patient-reported information
Baseline characteristics n = 1000
Age in years [mean (SD)] 38.4 (11.2)
Age in years at MS diagnosis [mean (SD)] 31.0 (10.7)
Disease duration in years [mean (SD)] 7.3 (6.7)










 Not determined/unknown (%) 4.7
EDSS score, median (IQR) 2.5 (2.5)
Number of relapses during last 24 months, median (IQR) 1.0 (2.0)
Number of reported onset symptoms, median (IQR) 2.0 (2.0)
MS onset  symptomsa
 Dysesthesias (%) 53.3
 Motor disturbances (%) 53.0
 Impaired vision (%) 44.4
 Exhaustibility (%) 25.5
 Concentration or memory problems (%) 11.2
 Bladder dysfunctions (%) 10.3
 Depressed mood (%) 7.7
 Tremor (%) 6.5
 Hearing impairment/speech problems/dysphagia (%) 5.5
 Sexual disturbances (%) 3.4
 Bowel voiding dysfunction (%) 3.4
 Euphoric mood (%) 1.0
Table 3  Therapies and comorbidities of the first 1000 REGIMS par-
ticipants at baseline
IQR interquartile range, MS multiple sclerosis
Number of prior MS therapies, median (IQR) 1.0 (1.0)
Duration of current MS therapy in years, median (IQR) 1.0 (2.0)








 Glatiramer acetate (%) 3.4
 Other (%) 2.6
Comorbidities




 Migraine and/or tension type headache (%) 13.0
 Hypo- or hyperthyroidism (%) 11.7
 Herpes infection (%) 10.2
 Hair loss (%) 5.9
 Recurring urinary tract infection (%) 4.7
 Arthralgia (%) 3.9
 Cardiac arrhythmias (%) 2.6
 Other autoimmune diseases (%) 2.2
 Diabetes mellitus (%) 2.0
 Cancer (%) 1.6
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medication and (S)AEs can be detected at an early time 
point. The challenge of this approach is that the software 
maintenance of the different tools that are provided by dif-
ferent companies is logistically complex and cost- and per-
sonnel-intensive. Here, two alternative approaches are pref-
erable: implementation of the pharmacovigilance items in 
the existing practice or hospital software, or limitation of the 
number of software tools for the pharmacovigilance docu-
mentation to the two to three most frequently used ones. The 
first approach is most convenient for the documenting center, 
but implies dealing with many different software companies. 
The latter approach includes double documentation for a 
small number of patients, but restriction to very few tools.
Recruitment of Centers Center recruitment is an impor-
tant issue for each new registry. Practices often have a high 
workload and no possibility of or interest in investing time 
for patient recruitment for scientific or quality-assurance 
purposes which are done on an optional basis. However, 
outpatient services are of high relevance in registries, since 
patients are seen on a regular basis, and reflect clinical 
routine care. Motivation strategies to convince centers to 
participate have to be developed. In this process, financial 
incentives have to be weighed against nonmonetary advan-
tages. In the REGIMS registry, a combination of incentives 
is applied. A documentation fee of €50 is paid for baseline, 
and €15 for follow-up documentation (in 2019), respec-
tively. Additionally, AE reports are provided and a newslet-
ter including center-specific recruitment information is sent 
on a regular basis. The motivation strategy also includes 
a rising awareness of pharmacovigilance questions in the 
dynamic MS field.
Recruitment of MS Patients In contrast to clinical trials, 
it is of high importance in registries to continuously include 
new patients, and to be as complete as possible. While cent-
ers are generally motivated at the beginning, a “motivational 
pause” after a certain number of patients often occurs, and 
only follow-up documentation of already included patients 
is done. There may be many reasons for this observation, 
but documentation always relies on motivated people, study 
nurses and physicians in the centers. Thus, recruitment 
works effectively if integrated into routine clinical practice, 
which is not feasible in every center, and motivation of the 
recruiting team is crucial for the development of a registry. 
Factors that increase motivation are generally short and con-
cise data items, easily implementable into the daily routine 
process of care with low or no training demands and no 
documentation reliance on one specific professional group 
only. In addition, regular feedback on recruited patient num-
bers and availability of own data are motivating factors.
Selection and Treatment Bias One aim of REGIMS was 
to document AEs in patients with newly approved immune 
system modifying treatments. Thus, due to the design of the 
registry, the majority of REGIMS patients are treated with 
a second-line therapy at baseline and the proportion of this 
patient group is higher than in the average German MS pop-
ulation [2, 17]. Therefore, the majority of the centers recruit 
patients on highly active drugs that were only approved in 
recent years (i.e., natalizumab, fingolimod, alemtuzumab, 
and ocrelizumab) and if they can ensure they can see the 
patients on a regular basis, e.g., for the administration or 
monitoring of the treatment. In contrast, patients on inter-
feron, glatiramer acetate, and azathioprine are less often 
recruited. A potential reason for this selection is that inter-
feron treatment has been well established for many years, 
with a known side effect profile, and patients are often not 
seen on a regular basis by a center. But it is important to 
establish a comparison group within a pharmacovigilance 
registry to be able to decide if signals or risks in patients on 
a specific (new) drug are higher than in those on standard 
or basic treatment. Patients in REGIMS so far may not be 
representative for the population of German patients treated 
with MS immunotherapies, and disease severity might be 
slightly higher among them. However, with respect to basic 
demographic characteristics and disease characteristics, such 
as age at disease onset and clinical course of MS, patients 
in REGIMS are comparable with the German MS popula-
tion [17–19]. As participation in the REGIMS registry is 
voluntary for the centers and the patients, there are no data 
available on the number of patients who were invited at the 
study sites but refused to participate; hence, we can give 
no estimate of the overall enrollment. However, the partici-
pating centers are asked to inform all eligible MS patients 
about the registry, and currently there is no upper limit to 
the number of REGIMS participants.
Patient-Based Documentation Another strength of 
REGIMS is that the medical documentation is comple-
mented by longitudinal patient self-reports, providing a more 
detailed assessment of a patient’s disease status and living 
situation over time. It has been shown that non-adherence 
may occur due to AEs or lack of efficacy of medication [20, 
21] or different living situations. This issue may be detected 
early by patient-based documentation.
Data Quality High-quality data are ensured by standard-
ized procedures regarding data entry via the software tools, 
plausibility checks during and after data entry, and training 
of every new study center. Furthermore, communication 
with and information for the study centers guarantees that 
centers are always up to date and informed about changes 
in the organizational or personnel structure of the project.
Creating a Pharmacovigilance Database The main objec-
tive of REGIMS is to create a pharmacovigilance database 
for MS in Germany, which includes safety data and PROs, 
such as quality of life, treatment adherence, healthcare uti-
lization, and costs for patients. REGIMS assesses the fre-
quency and type of AEs and SAEs across all MS drugs and 
differs in this respect from clinical observational and/or 
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application studies (non-interventional studies) of pharma-
ceutical companies, which do not allow comparisons across 
MS drugs and differ from each other in terms of the number 
and type of documented items. There is also the possibility 
of an intervention in the case of SAEs, and a cooperation 
with the responsible authorities can be established. Fur-
thermore, treatment switches, interruptions in treatment, 
and reasons for switching or interrupting treatment can be 
analyzed with the REGIMS registry data, which is an advan-
tage over post-marketing surveillance studies and registries 
implemented by marketing authorization holders, which are 
usually limited to one drug. The documentation of all AEs 
irrespective of the causality, i.e., even if causality is rated 
as “not assessable,” “unlikely,” or “not related,” is a clear 
strength of REGIMS as it allows the detection of events for 
which a causal association between the MS drug and the 
AE had not yet been considered. Our data show that phy-
sician-based follow-up documentation was conducted with 
a median follow-up time of 5.8 months, which allows the 
documentation of AEs and SAEs on a regular basis.
Other Methodological Issues A limitation might be 
that the validity of patient-reported information could be 
an issue. However, as physician-based documentation is 
also available, this can probably be neglected. Also, since 
questionnaires are sent to the patients directly, a slight time 
difference with the physician-based documentation may 
occur. As in any study, loss to follow-up plays an important 
role in the analyses and may bias the results. In REGIMS, 
loss to follow-up is minimized by the use of two different 
data sources (physician and patient reports). Moreover, the 
acceptance of the paper-based questionnaires by the patients 
is high (response rate > 90%).
5  Conclusions
Studies based on prospective registries, such as the immuno-
therapy registry REGIMS, represent a fundamental effort in 
planning, implementing, and logistics. However, the impor-
tance of such registry studies for clinical care and research 
is increasing as they focus on specific patient groups and/or 
rare diseases. Despite the logistic and procedural issues in 
establishing such a multicenter pharmacovigilance registry 
in Germany, the advantages outweigh the drawbacks. Phar-
macovigilance registries with standardized data assessment 
are important for monitoring highly specialized and rapidly 
changing drugs associated with significant financial costs 
and with possible AEs or SAEs that can occur after a long 
treatment period. In addition, data from registries such as the 
REGIMS registry allow the comparison of AEs and SAEs of 
newly approved drugs for which there is limited experience, 
especially regarding their long-term use. It is possible to 
directly analyze drug history and treatment switches, as well 
as interruptions in the treatment, to assess therapy adher-
ence and safety and to collect PROs. Future newly approved 
immune therapies can easily be added into the REGIMS 
documentation, and its results shall support physicians in 
finding the most appropriate therapy for a selected patient.
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